Iron Disorders
Matthew M. Heeney, MD, Editor Alan R. Cohen, MD, Editor Ferric (Fe +3 ) iron is ubiquitous in the earth’s environment and an essential metal in the biological processes of…
Waldenström Macrogloblinemia
Waldenström macroglobulinemia (WM) is an IgM-secreting B-cell lymphoproliferative disorder, with strong familial predisposition. MYD88 L265P and CXCR4 WHIM mutations are common in WM and support the growth and survival of…
Novel Targeted Agents in the Treatment of Multiple Myeloma
New, next-generation targeted treatment strategies are required to improve outcomes in patients with multiple myeloma (MM). Monoclonal antibodies, cell signaling inhibitors, and selective therapies targeting the bone marrow microenvironment have…
Immunotherapy Strategies in Multiple Myeloma
Multiple myeloma (MM) is a B-cell malignancy characterized by the clonal proliferation of malignant plasma cells in the bone marrow and the development of osteolytic bone lesions. MM has emerged…
Relapsed and Refractory Multiple Myeloma
New treatment options for patients with myeloma have helped to change the natural history of this disease, even in the context of relapsed disease. For standard-risk patients, doublet-based therapy may…
Allogeneic Stem Cell Transplantation for Multiple Myeloma
Prospective trials comparing tandem autologous stem cell transplantation (ASCT) with ASCT followed by allogeneic stem cell transplantation (AlloSCT) have shown mixed results with regard to progression-free and overall survival rates….
Maintenance Therapy for Multiple Myeloma
Multiple myeloma (MM) is a neoplasm typical of the elderly, with median age at diagnosis of 70 years, and approximately 65% of patients older than 65 years. Many advances have been made…
Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation
Considerable progress has been recently made in the treatment of elderly patients with multiple myeloma (MM). In Europe the combination of thalidomide with melphalan and prednisone and of bortezomib with…
Treatment of Transplant-Eligible Patients with Multiple Myeloma in 2014
Induction regimens containing a proteasome inhibitor and/or immunomodulatory agent with dexamethasone result in rapid disease control before autologous stem cell transplantation (ASCT). ASCT followed by consolidation and/or maintenance further improves…
Diagnosis and Risk Stratification in Multiple Myeloma
Multiple myeloma (MM) is a tumor of monoclonal plasma cells, which produce a monoclonal antibody and expand predominantly in the bone marrow. Patients present with hypercalcemia, renal impairment, anemia, and/or…
